Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Hovione Buys Stake in Zhejiang Hisyn

publication date: Mar 3, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Hovione, a Portuguese maker of active pharmaceutical ingredients, paid “in excess” of 13 million euros ($19.5 million) to buy 75% of the capital of Zhejiang Hisyn Pharmaceutical. Like Hovione, Zhejiang Hisyn is in the business of manufacturing active pharmaceutical ingredients. Hovione said the investment in Hisyn will lower its production costs while increasing production. With the lower costs, Hovione said it would be able to supply APIs to pharmas in China, India and Brazil. More details...

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...